Relmada Therapeutics Inc. (RLMD) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Relmada Therapeutics Inc.

    NASDAQ: RLMD · Real-Time Price · USD
    1.65
    0.28 (20.44%)
    At close: Sep 05, 2025, 3:59 PM
    1.63
    -1.13%
    After-hours: Sep 05, 2025, 07:50 PM EDT

    Relmada Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a 1.26K
    Gross Profit
    		 n/a n/a n/a -1.26K
    Operating Income
    		 -83.89M -103.7M -161.25M -125.7M
    Interest Income
    		 3.53M 5.15M 2.66M 1.2M
    Pretax Income
    		 -79.98M -98.79M -157.04M -125.75M
    Net Income
    		 -79.98M -98.79M -157.04M -125.75M
    Selling & General & Admin
    		 37.72M 48.9M 47.93M 35.08M
    Research & Development
    		 46.18M 54.81M 113.32M 90.62M
    Other Expenses
    		 -475 n/a n/a n/a
    Operating Expenses
    		 83.89M 103.7M 161.25M 125.7M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 83.89M 103.7M 161.25M 125.7M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 30.16M 30.1M 29.63M 17.55M
    Shares Outstanding (Diluted)
    		 30.16M 30.1M 29.63M 17.55M
    EPS (Basic)
    		 -2.65 -3.28 -5.3 -7.16
    EPS (Diluted)
    		 -2.65 -3.28 -5.3 -7.16
    EBITDA
    		 -79.98M 4.91M -157.04M -125.75M
    EBIT
    		 -79.98M -98.79M -157.04M -125.75M
    Depreciation & Amortization
    		 83.89M 103.7M 2K 1.26K

    Add to Watchlist